Monte Rosa Therapeutics (GLUE) Gains from Investment Securities (2023 - 2025)
Historic Gains from Investment Securities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $14.9 million.
- Monte Rosa Therapeutics' Gains from Investment Securities rose 2891.64% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 2891.64%. This contributed to the annual value of $11.6 million for FY2024, which is 2335.66% up from last year.
- Monte Rosa Therapeutics' Gains from Investment Securities amounted to $14.9 million in Q3 2025, which was up 2891.64% from $15.2 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Gains from Investment Securities ranged from a high of $15.2 million in Q2 2025 and a low of -$131000.0 during Q1 2023
- Over the past 3 years, Monte Rosa Therapeutics' median Gains from Investment Securities value was $11.5 million (recorded in 2024), while the average stood at $9.4 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 903900.0% in 2024, then crashed by 9949.62% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Gains from Investment Securities (Quarter) stood at $9.5 million in 2023, then rose by 22.15% to $11.6 million in 2024, then increased by 28.92% to $14.9 million in 2025.
- Its Gains from Investment Securities stands at $14.9 million for Q3 2025, versus $15.2 million for Q2 2025 and $59000.0 for Q1 2025.